SCHEMBL2237173

SCHEMBL2237173

Cc1ccc2c(c1)-n1cnc(/C=C3\CCCN(C(=O)OC(C)(C)C)C3=O)c1CC2

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
GABRA1 P14867 4/20 0.34
GABRG2 P18507 4/20 0.34
GABRB3 P28472 4/20 0.34
GABRA5 P31644 4/20 0.34
GABRA3 P34903 4/20 0.34
GABRA6 Q16445 4/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
BRD4 O60885 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
ESR2 Q92731 1/20 0.32
CYP11B2 P19099 1/20 0.32
CHRM4 P08173 1/20 0.32
DRD2 P14416 1/20 0.32
HTR7 P34969 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2233683 0.93 KDM4E (0.41) KDM4EGABRA1GABRG2GABRB3GABRA5
SCHEMBL2234771 0.89 NOTUM (0.36)
SCHEMBL2234012 0.86 BUB1 (0.33) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2234009 0.86 BUB1 (0.33) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2234658 0.85 PDK1 (0.36) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2235005 0.85 NOTUM (0.39) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2236285 0.84 NOTUM (0.38)
SCHEMBL2235353 0.83 GABRA1 (0.35) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2233604 0.83 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2233616 0.83 L3MBTL1 (0.35) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-01 US disclosed
EP-2361910-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY Taisho Pharmaceutical Co., Ltd. (JP) 2011-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAF1, TAF5, TAF11 KDM4E 1219/4885GABRA1 1783/4885GABRG2 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.